These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 12619222

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalapril.
    Chatzikyrkou C, Haller H, Menne J.
    Expert Opin Pharmacother; 2009 Aug; 10(11):1833-40. PubMed ID: 19527194
    [Abstract] [Full Text] [Related]

  • 7. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study.
    Barrios V, Escobar C, de la Figuera M, Llisterri JL, Honorato J, Segura J, Calderón A.
    Cardiovasc Ther; 2008 Aug; 26(1):2-9. PubMed ID: 18466416
    [Abstract] [Full Text] [Related]

  • 8. Omission of drug dose information.
    Hollenberg NK.
    Arch Intern Med; 2006 Feb 13; 166(3):368; author reply 368-9. PubMed ID: 16476880
    [No Abstract] [Full Text] [Related]

  • 9. Clevidipine: an ultra short-acting calcium channel antagonist for acute hypertension.
    Kenyon KW.
    Ann Pharmacother; 2009 Jul 13; 43(7):1258-65. PubMed ID: 19584385
    [Abstract] [Full Text] [Related]

  • 10. [Usefulness of long-acting Ca antagonist in hypertensive patients with metabolic syndrome].
    Takishita S.
    Nihon Rinsho; 2006 Dec 28; 64 Suppl 9():607-10. PubMed ID: 17458290
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Antihypertensive therapy. Can a calcium antagonist stop arteriosclerosis?].
    MMW Fortschr Med; 2001 May 31; 143(22):53. PubMed ID: 11460409
    [No Abstract] [Full Text] [Related]

  • 17. Nifedipine trials.
    Rafflenbeul W.
    Circulation; 1996 Apr 01; 93(7):1473-4. PubMed ID: 8641042
    [No Abstract] [Full Text] [Related]

  • 18. Acute antihypertensive effects of calcium channel blockers are not affected by calcium supplementation in patients with essential hypertension.
    Sato K, Dohi Y, Miyagawa K, Kojima M.
    Jpn Heart J; 1998 May 01; 39(3):347-53. PubMed ID: 9711186
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.
    Oparil S, Weber M.
    Postgrad Med; 2009 Mar 01; 121(2):25-39. PubMed ID: 19332960
    [Abstract] [Full Text] [Related]

  • 20. [Calcium antagonists lower not only blood pressure. Arteriosclerosis is braked too].
    MMW Fortschr Med; 2001 Nov 15; 143(46):60. PubMed ID: 11759606
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.